As per MRFR analysis, the US Heart Transplant Market Size was estimated at 2.74 (USD Billion) in 2023. The US Heart Transplant Market Industry is expected to grow from 3.5(USD Billion) in 2024 to 9 (USD Billion) by 2035. The US Heart Transplant Market CAGR (growth rate) is expected to be around 8.965% during the forecast period (2025 - 2035).
The US Heart Transplant Market is witnessing several important trends that reflect advancements in medical technology and a growing understanding of patient needs. One key market driver is the increasing prevalence of end-stage heart failure, which has prompted more patients to seek heart transplantation as a treatment option. Moreover, the aging population in the US contributes to this trend as older adults often experience cardiac issues that may lead to transplantation.
Additionally, the development of innovative surgical techniques and improved post-operative care has enhanced transplant success rates, driving more patients to opt for this life-saving procedure. Opportunities in the US market can be captured through the expansion of donor programs and better allocation of donor hearts. Increased awareness and education regarding organ donation among the general public are crucial.
Furthermore, initiatives that streamline the transplant process can lead to quicker patient recovery times and improved quality of life, making heart transplants more appealing to patients and healthcare providers alike. Recent times have also seen a trend toward the utilization of technology in matching donors with recipients more effectively. The use of artificial intelligence and data analytics is helping to optimize allocation processes, ensuring that donor hearts are matched with patients who need them the most urgently.
Additionally, patient-centric approaches are gaining traction, with more emphasis on personalized medicine and tailored postoperative support. All these factors combined are transforming the landscape of the heart transplant market in the US, reflecting a proactive approach in addressing heart failure and improving the overall effectiveness of heart transplant procedures.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of heart diseases in the United States is a significant driver of growth in the US Heart Transplant Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 697,000 people died from heart disease in 2020, accounting for 1 in every 5 deaths in the nation. This staggering statistic underscores the urgent need for effective treatments, including heart transplants, which is expected to drive market growth as more patients seek life-saving surgeries.
Furthermore, the American Heart Association has projected that by 2030, nearly 43.9% of the U.S. population could have some form of cardiovascular disease, creating an expanded patient base requiring transplantation. The increasing number of patients encourages investment in medical procedures, further propelling the US Heart Transplant Market.
Technological advancements in surgical procedures and post-operative care are catalysts for growth in the US Heart Transplant Market Industry. Cutting-edge techniques, such as minimally invasive surgery and improved immunosuppressive therapies, have significantly improved transplant success rates. A report by the Organ Procurement and Transplantation Network indicates that the one-year survival rate for heart transplant recipients improved from around 86% in 1990 to approximately 90% in recent years.
This advancement in technology is directly linked to major organizations such as the National Institutes of Health, which allocates substantial funding for Research and Development to enhance transplantation techniques. As these technologies continue to evolve, patient outcomes will improve, attracting more individuals who may benefit from heart transplants.
Efforts to raise awareness about the benefits of organ donation are contributing to the growth of the US Heart Transplant Market Industry. Campaigns led by organizations like Donate Life America have resulted in increased registration of organ donors. For instance, the National Donate Life Registry reported that as of January 2022, there were over 175 million registered organ donors in the United States, an increase of over 10% compared to previous years.
This heightened awareness not only leads to more available organs for transplantation but also encourages potential heart transplant recipients to seek evaluation and treatments. The more people are educated about the importance of organ donation, the more successful the US Heart Transplant Market will become, supporting its upward trajectory.
Government support through policies and funding for organ transplantation is integral to the expansion of the US Heart Transplant Market Industry. Federal initiatives, such as the Organ Transplantation Reform Act, have laid the groundwork for a structured approach toward improving organ donation systems and transplantation processes. As of 2022, the U.S. Department of Health and Human Services increased its funding for organ transplantation programs by 5%, directly impacting the availability of resources for transplant centers across the country.
This support not only increases the operational capabilities of these centers but also enhances patient care, leading to better transplant outcomes. Ultimately, government intervention creates a more favorable market environment, contributing to steady growth in the US Heart Transplant Market.
The US Heart Transplant Market has shown significant growth, particularly highlighted by its segmentation based on surgery type, which plays a crucial role in the treatment of advanced heart failure. In recent years, the demand for advanced surgical methods, such as Ventricular Assist Devices (VADs) and Total Artificial Hearts (TAHs), has become increasingly relevant, given the rising prevalence of heart diseases across the United States.
This is driven by various factors, including an aging population, lifestyle choices leading to cardiac ailments, and an increase in the number of patients awaiting transplants. The use of VADs has become a pivotal option for patients, serving as both a bridge to heart transplantation and a destination therapy, thereby enhancing patient longevity and quality of life.
TAHs offer a complete solution, particularly for patients who are not candidates for heart transplants, contributing significantly to improving mortality rates in severe heart failure cases. Furthermore, the growing trends in technology and innovation within the US healthcare sector have configured these surgical types to be more efficient, with better outcomes and fewer complications, which is vital for both surgeons and patients.
Additionally, the Other category, which encompasses various supportive and related surgeries, provides an essential platform for customized patient care. The synergy between various procedures and devices not only fills the gaps in traditional heart management techniques but also reflects the evolving capabilities within the US Heart Transplant Market industry to adapt to patient needs and technological advancements. Overall, the exploration of surgery types within this market reveals pivotal insights about how advanced surgical options are reshaping treatment paradigms and addressing the significant gap in heart transplant availability and patient care throughout the United States.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The End User segment of the US Heart Transplant Market comprises various critical entities such as hospitals, cardiac institutes, and other medical facilities, each playing a pivotal role in the heart transplant process. Hospitals act as primary caregivers, providing a wide range of treatments and resources, including surgical interventions and post-operative care, essential for patient recovery and monitoring.
Cardiac institutes specialize in heart-related conditions and offer advanced research, treatment protocols, and educational support, thus significantly contributing to the overall efficacy of heart transplant procedures. The 'Others' category may include outpatient surgery centers and rehabilitation facilities that play supportive roles in patient pre-and post-transplant care.
This segmentation reveals the interdependence of different healthcare facilities in enhancing patient outcomes and underscores the collaborative nature of cardiac care in the US. The growing prevalence of heart diseases and the increasing demand for transplant surgeries further emphasize the importance of these facilities in the US Heart Transplant Market, driving advancements in techniques and technologies for better surgical results.
As healthcare systems continue to evolve, these End Users are crucial in adapting to new trends and addressing emerging challenges within the industry.
The US Heart Transplant Market is an evolving landscape characterized by a growing demand for transplantable organs, advanced surgical techniques, and innovative therapies that enhance transplant success. Within this market, several players are vying for a position of leadership, driven by increased investments in research and development, the emergence of cutting-edge medical technologies, and a supportive regulatory environment.
The competitive insights reveal a diverse mix of established companies and newer entrants that are focused on providing comprehensive solutions for heart transplant procedures and post-transplant care. These companies compete not only based on the efficacy of their products and services but also on factors such as patient outcomes, cost-effectiveness, and their ability to navigate the complex healthcare ecosystem.
Organogenesis stands as a notable player in the US Heart Transplant Market, recognized for its innovative approaches to tissue regeneration and wound healing. The company has developed a strong portfolio of advanced biological products that support the recovery and rehabilitation of transplant patients. One of its key strengths is its commitment to research, leading to the continual enhancement of its product offerings, which cater to the specific needs of heart transplant recipients.
Furthermore, its effective collaborations with clinical partners and robust distribution networks have cemented its position within the market, ensuring that their solutions are accessible across various healthcare settings in the US. Organogenesis has also focused on educating healthcare professionals about the importance of regenerative medicine, thereby increasing awareness and adoption of its technologies in the field of heart transplantation.
Asahi Kasei is another significant entity within the US Heart Transplant Market, known for its comprehensive range of medical products and services that facilitate heart surgeries and post-operative care. The company specializes in advanced biomedical materials and has established a solid presence through its innovative offerings, including devices used during transplantation procedures and biocompatible materials for cardiac applications.
One of Asahi Kasei's strengths lies in its strong R&D capabilities, which have led to numerous technological advancements that improve patient outcomes. The firm has also pursued strategic mergers and acquisitions to expand its product portfolio and enhance its market footprint in the US. By integrating various technologies and strengthening their supply chain, Asahi Kasei has successfully positioned itself to meet the growing needs of the heart transplant community, showcasing its commitment to improving the quality of life for patients undergoing cardiac procedures.
The US Heart Transplant Market has seen significant developments in recent months, particularly with advancements in organ preservation and the use of innovative technologies. Companies like TransMedics are making strides with their Organ Care System, which enhances the viability of donor hearts, thereby improving transplant outcomes. Meanwhile, Medtronic and Abbott Laboratories are focusing on devices that support heart function, such as ventricular assist devices and total artificial hearts, which play a critical role in managing patients awaiting transplants.
In terms of mergers and acquisitions, Astellas Pharma announced the acquisition of a US-based biotech focused on immunology in September 2023, highlighting the increasing interest in novel therapies for transplant rejection. Additionally, Boston Scientific is exploring strategic partnerships to enhance its cardiac interventions portfolio.
Over the past two to three years, the US Heart Transplant Market has experienced notable growth, with an increase in transplant surgeries attributed to expanded donor criteria and technological improvements that have broadened donor heart availability. As of early 2023, over 4,000 heart transplants were performed in the US, reflecting a steady upward trend in procedures and patient outcomes in the heart transplant sector.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 2.74(USD Billion) |
| MARKET SIZE 2024 | 3.5(USD Billion) |
| MARKET SIZE 2035 | 9.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.965% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Organogenesis, Asahi Kasei, TransMedics, NantKwest, Medtronic, Abbott Laboratories, Boston Scientific, Baxter International, Sientra, Thermo Fisher Scientific, Elekta, Bridge to Life, Xenotransplantation International, Astellas Pharma, Mylan |
| SEGMENTS COVERED | Surgery type, End User |
| KEY MARKET OPPORTUNITIES | Increased donor organ availability, Advancements in transplant technology, Growing patient population, Enhanced post-transplant care, Government funding initiatives |
| KEY MARKET DYNAMICS | Rising heart disease prevalence, Advancements in surgical technology, Increased government funding, Growing organ donation awareness, Aging population demographics |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Heart Transplant Market is expected to be valued at 3.5 billion USD in 2024.
By 2035, the overall market is anticipated to reach a value of 9.0 billion USD.
The projected CAGR for the US Heart Transplant Market during the period from 2025 to 2035 is 8.965%.
In 2024, the Ventricular Assist Devices segment is valued at 1.4 billion USD, making it the largest segment.
The Total Artificial Hearts segment is expected to be valued at 1.0 billion USD in 2024.
Major players in the market include Organogenesis, Asahi Kasei, TransMedics, and Medtronic among others.
The 'Others' segment is projected to be valued at 3.0 billion USD by 2035.
The market is expected to grow continuously, showcasing a compound annual growth rate of 8.965% from 2025 to 2035.
Challenges may arise from regulatory hurdles and technological advancements impacting the adoption of alternatives.
The Ventricular Assist Devices segment is expected to reach a market value of 3.5 billion USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
